Open AccessAn Open-Label, Randomized, Prospective, Comparative, Three-Arm Clinical Trial to Evaluate the Safety and Effectiveness of Apremilast with Three Different Titration Methods in Patients with Chronic Plaque Psoriasis in India
Author(s) -
Vishalakshi Viswanath,
Pradnya Joshi,
Prakash Lawate,
Dakshata Tare,
Dhiraj Dhoot,
Namrata Mahadkar,
Hanmant Barkate
Publication year - 2022
Publication title -
psoriasis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.066
H-Index - 4
ISSN - 2230-326X
DOI - 10.2147/ptt.s357184
Subject(s) - apremilast , medicine , discontinuation , adverse effect , plaque psoriasis , randomized controlled trial , psoriasis , nausea , dermatology , psoriatic arthritis
To minimize adverse effects (AEs), apremilast is recommended to titrate at the initiation of therapy. But still, many patients experience AEs, resulting in discontinuation of therapy. As a result, many dermatologists have adapted to further titrate apremilast in different ways. The present study was planned to evaluate the safety and effectiveness of apremilast in different dose titration methods as initiation therapy in the treatment of plaque psoriasis.